The molecular mechanism of chemoresistance acquisition resulting from high expression of MDM2, which we proposed here, might contribute to the poor prognosis for breast cancer (this article, Figure 1) and non-small cell lung cancer [28] patients with high expression of MDM2. Here, MDM2 is linked to non-small cell lung carcinoma.